Nippon Kayaku's NK105 fails breast cancer Phase III

NK105 micellar paclitaxel from Nippon Kayaku Co. Ltd. (Tokyo:4272) missed the primary endpoint in a Phase III study to treat metastatic or recurrent breast cancer.

NanoCarrier Co. Ltd. (Tokyo:4571), which had licensed the product to Nippon, fell Y190 (15%) to Y1,050 on Wednesday. In a statement, NanoCarrier said the Phase III failure does not reflect its current pipeline, which includes modified compounds with longer half lives in human plasma. ...